Determine the necessary mass, volume, or concentration for preparing a solution.
RP-6306 - ≥99% , CAS No.2719793-90-3
AVAILABLE TO ORDER
GRADE & PURITY ≥99%
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
224,000+ research products · Triple ISO certified · COA & SDS available for every product · Same-day shipping on in-stock items
Why this grade
≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Overview
RP-6306\t((S)-RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC 50 of 14 nM. RP-6306 shows a high degree of selectivity over other kinases in cellular binding assays. RP-6306 shows anticancer effects
In Vitro
RP-6306 (500 nM; for 24 h) treatment induces pan-γH2AX in an HCC1569 breast cancer cell line, indicating that tumour-derived CCNE1 amplification also renders cells vulnerable to DNA damage induction following PKMYT1 inhibition. RP-6306 treatment causes unscheduled activation of CDK1 selectively in CCNE1-overexpressing cells, promoting early mitosis in cells undergoing DNA synthesis. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
RP-6306 (15, 50, and 300 ppm; oral; daily; for 21 days) results in a statistically significant and dose-dependent reduction in OVCAR3 tumor growth in CCNE1-amplified ovarian xenograft model (OVCAR3) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: OVCAR3-bearing mice Dosage: 15, 50, and 300 ppm (equivalent to approximately 3, 10, and 60 mg/kg/day) Administration: Oral; daily; for 21 days Result: Resulted in a statistically significant and dose-dependent reduction in OVCAR3 tumor growth.
Form:Solid
IC50& Target:IC50: 14 nM (PKMYT1)
Specifications
Specifications & Purity
≥99%
Biochemical and Physiological Mechanisms
RP-6306\t((S)-RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC 50 of 14 nM. RP-6306 shows a high degree of selectivity over other kinases in cellular binding assays. RP-6306 shows anticancer effects.
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Purity
≥99%
Names and Identifiers
| Molecular Weight | 324.38 |
|---|
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificates（CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemical and Physical Properties
| Solubility | DMSO : 50 mg/mL (154.14 mM; Need ultrasonic) |
|---|
Solution Calculators
Reviews
Customer Reviews
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.